Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY vs ABILIFY ASIMTUFII
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
>99% bound to albumin and alpha-1-acid glycoprotein.
>99% bound to serum albumin.
4.9 L/kg (high distribution into tissues).
4.9 L/kg, indicating extensive extravascular distribution.
Oral: 87% (tablet and solution); IM: 100%.
Intramuscular: 100% (as a depot suspension).
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Not approved for use in pediatric patients. Safety and efficacy have not been established.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Known hypersensitivity to aripiprazole or any of its excipients.
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY vs ABILIFY ASIMTUFII, answered by our medical review team.
ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY and ABILIFY ASIMTUFII depend on the specific clinical indication. These are both Atypical antipsychotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY and ABILIFY ASIMTUFII in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.